this drug has shown greater potency and activity in experimental and human leukemias and lymphomas by intravenous and oral routes of administration together with less cardiotoxicity than doxorubicin ( dx ) and daunorubicin ( dnr ) .
C0013089
doxorubicin
C0011015
daunorubicin